Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...
Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.
We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...
Clinical Trials Arena on MSN
Investor focus shifts to late-stage development in biotech, expert says
At OCTSC, an expert discussed the biotech funding environment, market trends and for all key stakeholders in the healthcare space.
Navan will be the first large company to debut without a fully functioning Securities and Exchange Commission.
Get the latest on INmune Bio’s Q3 2025 earnings: regulatory milestones, pipeline updates, and financial outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback